Background: Alzheimer's disease (AD), a cognitive dysfunction/dementia state amongst the
elders is characterized by irreversible neurodegeneration due to varied pathophysiology. Up till now,
anti-AD drugs having different pharmacology have been developed and used in clinic. Yet, these medications
are not curative and only lowering the AD associated symptoms. Improvement in treatment outcome
required drug targeting across the blood-brain barrier (BBB) to the central nervous system
(CNS) in optimal therapeutic concentration. Nanotechnology based diagnostic tools, drug carriers and
theranostics offer highly sensitive molecular detection, effective drug targeting and their combination.
Over the past decade, significant works have been done in this area and we have seen very remarkable
outocome in AD therapy. Various nanoparticles from organic and inorganic nanomaterial category have
successfully been investigated against AD.
Conclusion: This paper discussed the role of nanoparticles in early detection of AD, effective drug targeting
to brain and theranostic (diagnosis and therapy) approaches in AD's management.
Keywords: Alzheimer's disease, blood brain barrier, diagnosis, theranostic, nanoparticles, nanomedicines.
Rights & PermissionsPrintExport